195 related articles for article (PubMed ID: 22871886)
1. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
Thoms JW; Dal Pra A; Anborgh PH; Christensen E; Fleshner N; Menard C; Chadwick K; Milosevic M; Catton C; Pintilie M; Chambers AF; Bristow RG
Br J Cancer; 2012 Aug; 107(5):840-6. PubMed ID: 22871886
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
3. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy.
Puzone R; Paleari L; Montefiore F; Ruggiero L; Puntoni M; Maffezzini M; Bobbio B; Marroni P; Libener R; Betta PG
Int J Biol Markers; 2010; 25(4):200-6. PubMed ID: 21161941
[TBL] [Abstract][Full Text] [Related]
6. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
8. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.
Dayyani F; Zurita AJ; Nogueras-González GM; Slack R; Millikan RE; Araujo JC; Gallick GE; Logothetis CJ; Corn PG
BMC Cancer; 2016 Sep; 16(1):721. PubMed ID: 27599544
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.
Elbaiomy MA; Akl T; Elhelaly R; El-Beshbishi W; El Ghonemy MS; Elzehery R
Curr Oncol; 2020 Oct; 27(5):e444-e450. PubMed ID: 33173383
[TBL] [Abstract][Full Text] [Related]
10. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Bramwell VH; Tuck AB; Chapman JA; Anborgh PH; Postenka CO; Al-Katib W; Shepherd LE; Han L; Wilson CF; Pritchard KI; Pollak MN; Chambers AF
Breast Cancer Res; 2014 Jan; 16(1):R8. PubMed ID: 24451146
[TBL] [Abstract][Full Text] [Related]
11. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
Goldberg H; Glicksman R; Woon D; Hoffman A; Shaikh H; Chandrasekar T; Klaassen Z; Wallis CJD; Ahmad AE; Sanmamed-Salgado N; Qu X; Moraes FY; Diamandis EP; Berlin A; Fleshner NE
BJU Int; 2021 Jun; 127(6):654-664. PubMed ID: 32926761
[TBL] [Abstract][Full Text] [Related]
12. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
13. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
14. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
15. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
16. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.
Prager AJ; Peng CR; Lita E; McNally D; Kaushal A; Sproull M; Compton K; Dahut WL; Figg WD; Citrin D; Camphausen KA
Biomark Med; 2013 Dec; 7(6):831-41. PubMed ID: 24266816
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
Lim AM; Rischin D; Fisher R; Cao H; Kwok K; Truong D; McArthur GA; Young RJ; Giaccia A; Peters L; Le QT
Clin Cancer Res; 2012 Jan; 18(1):301-7. PubMed ID: 22096023
[TBL] [Abstract][Full Text] [Related]
19. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
Anborgh PH; Wilson SM; Tuck AB; Winquist E; Schmidt N; Hart R; Kon S; Maeda M; Uede T; Stitt LW; Chambers AF
Clin Chem; 2009 May; 55(5):895-903. PubMed ID: 19325010
[TBL] [Abstract][Full Text] [Related]
20. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
